Peroxiredoxin V: A candidate breast tumor marker of population specificity

Elamin,Amany; Zhu,Hongxia; El Hassan,A. M.; Xu,Ningzhi; Ibrahim,Muntasir  E.

doi:10.3892/mco.2013.91

Peroxiredoxin V: A candidate breast tumor marker of population specificity

Authors:
- Amany Elamin
- Hongxia Zhu
- A. M. El Hassan
- Ningzhi Xu
- Muntasir E. Ibrahim
View Affiliations

Affiliations: Department of Molecular Biology, Institute of Endemic Diseases, University of Khartoum, Khartoum 11111, Sudan, Laboratory of Cell and Molecular Biology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China
Published online on: March 13, 2013 https://doi.org/10.3892/mco.2013.91
Pages: 541-549

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast and cervical cancers account for approximately 50% of all types of cancer in Sudanese women. In a previous preliminary proteomic study aimed to identify proteins that were differentially expressed between tumors and control tissues (n=24), we identified peroxiredoxin V (PrdxV) as a candidate tumor marker. Peroxiredoxins (Prdxs) are a family of multifunctional proteins that are involved in the cell protection against oxidative stress, modulation of intracellular signaling, and regulation of cell proliferation. Knockout animal models suggest that the regulation of these proteins may be a novel target for therapeutic interventions. A total of 91 tumors and 79 normal breast tissues obtained from a panel of 106 Sudanese breast cancer patients, as well as 31 paired tissue samples (tumors and controls) from Chinese cancer patients were included in this study. Tissue sections were examined using immunohistochemistry (IHC) for PrdxI, V and VI antibodies. The PrdxV mRNA pattern of expression was also investigated using in situ hybridization (ISH). The overall expression of the same Prdx family members was also examined in a panel of Chinese breast carcinoma and control samples. Statistical comparisons were performed between Prxds antibodies, and between available demographic and pathological parameters. The studied Prdxs were found to be overexpressed in both Sudanese and Chinese breast cancer and control samples. PrdxV was the only member of the Prdxs family to be significantly downregulated in Sudanese tumor samples, with only a few cases being immunoreactive for PrdxV (11%). Significant elevation was demonstrated between tumors and controls at both the protein (using IHC) (P=0.000) and mRNA (using ISH) (P=0.044) levels. However, the finding was more apparent and statistically significant at the protein level, suggesting the presence of post‑translational modification. These findings suggest that PrdxV is a tumor marker of population specificity. However, more studies are needed to investigate the applicability of PrdxV as a marker in Sudanese breast cancer patients and its potential implications in therapy.

View Figures

View References

1.	Greenberg JT and Demple B: Overproduction of peroxide-scavenging enzymes in Escherichia colisuppresses spontaneous mutagenesis and sensitivity to redox-cycling agents in oxyR-mutants. Embo J. 7:2611–2617. 1988.PubMed/NCBI
2.	Dietz KJ: The dual function of plant peroxiredoxins in antioxidant defence and redox signaling. Subcell Biochem. 44:267–294. 2007. View Article : Google Scholar : PubMed/NCBI
3.	Zhang B, Wang Y and Su Y: Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett. 286:154–160. 2009. View Article : Google Scholar : PubMed/NCBI
4.	Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA and Chae HZ: Overexpression of peroxiredoxin in human breast cancer. Anticancer Res. 21:2085–2090. 2001.PubMed/NCBI
5.	Karihtala P, Mantyniemi A, Kang SW, Kinnula VL and Soini Y: Peroxiredoxins in breast carcinoma. Clin Cancer Res. 9:3418–3424. 2003.PubMed/NCBI
6.	Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, Abraham JL, Bronson RT, Fujiwara Y, Orkin SH and Van Etten RA: Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature. 424:561–565. 2003. View Article : Google Scholar : PubMed/NCBI
7.	Lee TH, Kim SU, Yu SL, Kim SH, Park DS, Moon HB, Dho SH, Kwon KS, Kwon HJ, Han YH, et al: Peroxiredoxin II is essential for sustaining life span of erythrocytes in mice. Blood. 101:5033–5038. 2003. View Article : Google Scholar : PubMed/NCBI
8.	Wang X, Phelan SA, Forsman-Semb K, Taylor EF, Petros C, Brown A, Lerner CP and Paigen B: Mice with targeted mutation of peroxiredoxin 6 develop normally but are susceptible to oxidative stress. J Biol Chem. 278:25179–25190. 2003. View Article : Google Scholar : PubMed/NCBI
9.	De Simoni S, Goemaere J and Knoops B: Silencing of peroxiredoxin 3 and peroxiredoxin 5 reveals the role of mitochondrial peroxiredoxins in the protection of human neuroblastoma SH-SY5Y cells toward MPP⁺. Neurosci Lett. 433:219–224. 2008.PubMed/NCBI
10.	Seo MS, Kang SW, Kim K, Baines IC, Lee TH and Rhee SG: Identification of a new type of mammalian peroxiredoxin that forms an intramolecular disulfide as a reaction intermediate. J Biol Chem. 275:20346–20354. 2000. View Article : Google Scholar : PubMed/NCBI
11.	Kropotov AV, Grudinkin PS, Pleskach NM, Gavrilov BA, Tomilin NV and Zhivotovsky B: Downregulation of peroxiredoxin V stimulates formation of etoposide-induced double-strand DNA breaks. FEBS Lett. 572:75–79. 2004. View Article : Google Scholar : PubMed/NCBI
12.	Sambrook J, Fritsch EF and Maniatis T: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press; New York: pp. 1989
13.	Breitschopf H, Suchanek G, Gould RM, Colman DR and Lassmann H: In situ hybridization with digoxigenin-labeled probes: sensitive and reliable detection method applied to myelinating rat brain. Acta Neuropathol. 84:581–587. 1992. View Article : Google Scholar
14.	Cha MK, Suh KH and Kim IH: Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma. J Exp Clin Cancer Res. 28:932009. View Article : Google Scholar : PubMed/NCBI
15.	Immenschuh S and Baumgart-Vogt E: Peroxiredoxins, oxidative stress, and cell proliferation. Antioxid Redox Signal. 7:768–777. 2005. View Article : Google Scholar : PubMed/NCBI
16.	Chang TS, Jeong W, Choi SY, Yu S, Kang SW and Rhee SG: Regulation of peroxiredoxin I activity by Cdc2-mediated phosphorylation. J Biol Chem. 277:25370–25376. 2002. View Article : Google Scholar : PubMed/NCBI
17.	Wagner E, Luche S, Penna L, Chevallet M, Van Dorsselaer A, Leize-Wagner E and Rabilloud T: A method for detection of overoxidation of cysteines: peroxiredoxins are oxidized in vivo at the active-site cysteine during oxidative stress. Biochem J. 366:777–785. 2002.PubMed/NCBI
18.	Lehtonen S: Localization and regulation of peroxiredoxins in human lung and lung diseases. Oulun Yliopisto; Oulu: 2005
19.	Moll R, Mitze M, Frixen UH and Birchmeier W: Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol. 143:1731–1742. 1993.PubMed/NCBI
20.	Vos CB, Cleton-Jansen AM, Berx G, de Leeuw WJ, ter Haar NT, van Roy F, Cornelisse CJ, Peterse JL and van de Vijver MJ: E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer. 76:1131–1133. 1997. View Article : Google Scholar : PubMed/NCBI
21.	Gown AM: Genogenic immunohistochemistry: a new era in diagnostic immunohistochemistry. Curr Diagn Pathol. 8:193–200. 2002. View Article : Google Scholar
22.	Wood ZA, Poole LB and Karplus PA: Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. Science. 300:650–653. 2003. View Article : Google Scholar : PubMed/NCBI
23.	Rhee SG, Jeong W, Chang TS and Woo HA: Sulfiredoxin, the cysteine sulfinic acid reductase specific to 2-Cys peroxiredoxin: its discovery, mechanism of action, and biological significance. Kidney Int Suppl. 106:S3–S8. 2007. View Article : Google Scholar : PubMed/NCBI
24.	Zhou Y, Kok KH, Chun AC, Wong CM, Wu HW, Lin MC, Fung PC, Kung H and Jin DY: Mouse peroxiredoxin V is a thioredoxin peroxidase that inhibits p53-induced apoptosis. Biochem Biophys Res Commun. 268:921–927. 2000. View Article : Google Scholar : PubMed/NCBI
25.	Banmeyer I, Marchand C, Verhaeghe C, Vucic B, Rees JF and Knoops B: Overexpression of human peroxiredoxin 5 in subcellular compartments of Chinese hamster ovary cells: effects on cytotoxicity and DNA damage caused by peroxides. Free Radic Biol Med. 36:65–77. 2004. View Article : Google Scholar : PubMed/NCBI
26.	Kropotov A, Serikov V, Suh J, Smirnova A, Bashkirov V, Zhivotovsky B and Tomilin N: Constitutive expression of the human peroxiredoxin V gene contributes to protection of the genome from oxidative DNA lesions and to suppression of transcription of noncoding DNA. FEBS J. 273:2607–2617. 2006. View Article : Google Scholar : PubMed/NCBI
27.	Awadelkarim KD, Arizzi C, Elamin EO, Hamad HM, De Blasio P, Mekki SO, Osman I, Biunno I, Elwali NE, Mariani-Costantini R, et al: Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: implications for breast cancer in Africa. Histopathology. 52:445–456. 2008. View Article : Google Scholar : PubMed/NCBI
28.	Elgaili EM, Abuidris DO, Rahman M, Michalek AM and Mohammed SI: Breast cancer burden in central Sudan. Int J Womens Health. 2:77–82. 2010.
29.	Khaled HM: Breast cancer at diagnosis in women of Africa and the Middle East. Breast Cancer in Women of African Descent. Williams CKO, Olopade OI and Falkson CI: Springer; Dordrecht, The Netherlands: pp. 1975–2004. 2006
30.	Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, et al: Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol. 23:4287–4297. 2005. View Article : Google Scholar : PubMed/NCBI
31.	Carlson RW and Stockdale FE: The clinical biology of breast cancer. Annu Rev Med. 39:453–464. 1988. View Article : Google Scholar : PubMed/NCBI
32.	Ijaduola TG and Smith EB: Pattern of breast cancer among white-American, African-American, and nonimmigrant west-African women. J Natl Med Assoc. 90:547–551. 1998.PubMed/NCBI
33.	Masri MA, Abdel Seed NM, Fahal AH, Romano M, Baralle F, El Hassam AM and Ibrahim ME: Minor role for BRCA2 (exon11) and p53 (exon 5–9) among Sudanese breast cancer patients. Breast Cancer Res Treat. 71:145–147. 2002.PubMed/NCBI
34.	Awadelkarim KD, Aceto G, Veschi S, Elhaj A, Morgano A, Mohamedani AA, Eltayeb EA, Abuidris D, Di Gioacchino M, Battista P, et al: BRCA1 and BRCA2 status in a Central Sudanese series of breast cancer patients: interactions with genetic, ethnic and reproductive factors. Breast Cancer Res Treat. 102:189–199. 2007. View Article : Google Scholar : PubMed/NCBI
35.	Mahfoudh W, Bouaouina N, Ahmed SB, Gabbouj S, Shan J, Mathew R, Uhrhammer N, Bignon YJ, Troudi W, Elgaaied AB, et al: Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population. Mol Biol Rep. 39:1037–1046. 2012. View Article : Google Scholar : PubMed/NCBI
36.	Singh AK, Pandey A, Tewari M, Shukla HS and Pandey HP: Epigenetic silencing of BRCA1 gene associated with demographic and pathologic factors in sporadic breast cancer: a study of an Indian population. Eur J Cancer Prev. 20:478–483. 2011. View Article : Google Scholar : PubMed/NCBI
37.	Konecny M, Milly M, Zavodna K, Weismanova E, Gregorova J, Mlkva I, Ilencikova D, Kausitz J and Bartosova Z: Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia. Breast Cancer Res Treat. 126:119–130. 2011. View Article : Google Scholar : PubMed/NCBI
38.	Zhu K, Hunter S, Payne-Wilks K, Sutcliffe C, Bentley C, Roland CL and Williams SM: Potential differences in breast cancer risk factors based on CYP1A1 MspI and African-American-specific genotypes. Ethn Dis. 16:207–215. 2006.PubMed/NCBI